$BJDX News

Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness

Bluejay Diagnostics Completes Establishment Of Manufacturing Site For Symphony Cartridges, Reaching Contractual Milestone As It Advances Toward Regulatory Submission And Potential Commercialization

Bluejay Diagnostics Advances Rapid Biomarker Testing For Sepsis Patients

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Bluejay Diagnostics Advances Rapid Biomarker Testing For Sepsis Patients

Bluejay Diagnostics Reports SYMON-II Baseline Data Showing Diverse Critically Ill Sepsis Population And Meaningful Mortality Events Supporting IL-6 Evaluation For 28-Day Mortality Risk

Bluejay Diagnostics Federal Healthcare Partnership Builds Commercial Pathway Ahead of FDA Clearance

Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets

Bluejay Diagnostics And Lovell Announce Distribution, Co-Marketing And Strategic Partnership To Support Introduction Of Bluejay’s Products Into U.S. Federal Healthcare Market

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

Bluejay Diagnostics Q2 EPS $(1.12) Up From $(5.64) YoY

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

Bluejay Diagnostics Completes Patient Enrollment In SYMON-II Multicenter Clinical Validation Study

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

What's Going On With Bluejay Diagnostics Shares On Wednesday?

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bluejay Diagnostics Announces $8.5M Private Placement Of 3,655,917 Shares, With Series G And H Warrants At A Combined Price Of $2.325; Potential Additional Gross Proceeds To The Company From The Series G Warrants And The Short-Term Series H Warrants, If Fully Exercised On A Cash Basis, Will Be ~$15.1M

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

Why Is Bluejay Diagnostics Stock Soaring Tuesday?

Bluejay Diagnostics Announces Strategic Partnership With Argonaut Manufacturing Services To Support Advancement Of Bluejay's Symphony Platform